

RECKITT BENCKISER GROUP PLC

**2024 SHARE BUYBACK PROGRAMME
COMPLETION OF SECOND TRANCHE AND COMMENCEMENT OF THIRD TRANCHE**

Reckitt Benckiser Group plc ("**Reckitt**" or the "**Company**") confirms the successful completion of the second tranche of £250m (the "**Second Tranche**") of its 2024 £1 billion share buyback programme (the "**Programme**") announced on 2 October 2024.

Under the Second Tranche, between 2 October 2024 and 10 December 2024, the Company has purchased 5,257,388 ordinary shares of 10p each (the "**Ordinary Shares**") at an average price of £47.5521, and which are now held in treasury.

Further to the announcement on 9 December 2024, the Company confirms that the third tranche of the Programme (the "**Third Tranche**") to return up to a further £500 million of capital to shareholders, will commence on 12 December 2024 and will end on or before 30 June 2025. As previously announced, the purpose of the Third Tranche is to reduce the share capital of the Company. The Third Tranche will take place within the limitations of the authority granted to the Board by shareholders at the Company's Annual General Meeting on 2 May 2024. Pursuant to that authority, the maximum number of shares which remain available for purchase under the Third Tranche is 50,000,000.

As previously announced, Reckitt has entered into an agreement with HSBC Bank plc ("**HSBC**") under which it has instructed HSBC to manage the Third Tranche of the Programme. HSBC will, acting as riskless principal, purchase Ordinary Shares for an aggregate purchase price of no greater than £500 million and will simultaneously sell such Ordinary Shares on to the Company. To the extent permitted by law, Ordinary Shares purchased under the Third Tranche of the Programme will be held in treasury.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

CONTACT DETAILS:

Nick Ashworth +44 (0) 7408 812350
Investor Relations

Catheryn O'Rourke +44 (0) 1753 217 800
General Counsel & Company Secretary

About Reckitt:

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com

* Reckitt is the trading name of the Reckitt Benckiser group of companies

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBRBDDUSBDGSG